ISU Abxis Co., Ltd.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

First Posted Date
2023-10-12
Last Posted Date
2024-07-29
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
24
Registration Number
NCT06081062
Locations
🇵🇭

St.Luke's Medical Center, Manila, Philippines

🇵🇭

Philippine General Hospital, Manila, Philippines

🇰🇷

Seoul Asan Center, Seoul, Songpa-gu, Korea, Republic of

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Phase 1
Completed
Conditions
Gaucher Disease
Interventions
Drug: Abcertin
Drug: EU-sourced Cerezyme
First Posted Date
2021-03-09
Last Posted Date
2021-04-05
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
42
Registration Number
NCT04787887
Locations
🇦🇺

Scientia Clinical Research Limited, Randwick, New South Wales, Australia

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Phase 1
Conditions
Solid Tumor
Interventions
Biological: ISU104
Drug: Cetuximab
First Posted Date
2018-06-11
Last Posted Date
2021-05-06
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
33
Registration Number
NCT03552406
Locations
🇰🇷

Kosin University Gospel Hospital, Busan, Korea, Republic of

🇰🇷

Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 2 locations

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

First Posted Date
2017-06-14
Last Posted Date
2020-11-10
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
11
Registration Number
NCT03186677
Locations
🇰🇷

Pusan National Univesity Hospital, Pusan, Korea, Republic of

🇰🇷

Yonsei University Medical Center, Seoul, Korea, Republic of

🇰🇷

Eulji University Hospital, Daejeon, Korea, Republic of

Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients

First Posted Date
2017-03-22
Last Posted Date
2017-03-22
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
146
Registration Number
NCT03087539
Locations
🇰🇷

Chonnam National University, Gwangju, Chonnam, Korea, Republic of

Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

Phase 3
Completed
Conditions
Gaucher Disease, Type 1
Interventions
Drug: ISU302
First Posted Date
2016-05-12
Last Posted Date
2017-07-12
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
8
Registration Number
NCT02770625

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

Completed
Conditions
Gaucher Disease
First Posted Date
2014-02-04
Last Posted Date
2014-02-04
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
5
Registration Number
NCT02053896

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

Phase 1
Completed
Conditions
Gaucher Disease
Interventions
Drug: Placebo
Drug: ISU302
First Posted Date
2013-06-19
Last Posted Date
2013-06-19
Lead Sponsor
ISU Abxis Co., Ltd.
Target Recruit Count
24
Registration Number
NCT01881633

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

Phase 3
Withdrawn
Conditions
Gaucher Disease
Interventions
Drug: Cerezyme®
Drug: ISU302
First Posted Date
2010-07-14
Last Posted Date
2016-08-23
Lead Sponsor
ISU Abxis Co., Ltd.
Registration Number
NCT01161914
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy